戻る
Bristol-Myers Squibb Co (BMY)価格
BMY 株価推移チャート
BMY 収入
Bristol-Myers Squibb Co
$54.22
-1.88%
$-1.03
終値： Jan 20, 16:00:00 GMT-5
$54.29
0.12%
$0.07
アフターマーケット：Jan 20, 20:00:00 GMT-5
B-
最終スコア
主要データ
前終値
$55.26
始値
$54.53
当日レンジ
$53.88 - $54.9
52週レンジ
$42.52 - $63.33
取引高
10.7M
平均取引高
15.4M
1株当たり利益(TTM)
2.96
配当利回り
4.59%
時価総額
$110.5B
BMYとは何ですか？
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.